Found "Early HTA": 405 results
Mission Report: Capacity Strengthening on Health Priority Setting and Institutionalising Health Technology Assessment (HTA)
EXECUTIVE SUMMARY
The Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand, undertook a mission to Colombo, Sri Lanka, supported by the World Bank Group. The mission aimed to support national efforts to strengthen capacity on health priority setting and institutiona
Workshop on Paying for Precision Medicine Sustainably in Asia: Reimbursement Barriers, Enablers, and Implications for HTA
Executive Summary
The use of Precision Medicine (PM) is increasing across Asia at a pace that outstrips the capacity of existing Health Technology Assessment (HTA) and reimbursement systems to respond. The “Workshop on Paying for Precision Medicine Sustainably in Asia: Reimbursement Barriers, Ena
Standard Cost List for Health Technology Assessment
The Standard Cost List for Health Technology Assessment in Thailand provides the foundational cost data for Health Technology Assessment (HTA) and economic evaluation studies. It supplies robust, context-specific cost data to inform evidence-based policy, specifically for developing and revising benefit packages under Thailand’s Universal Coverag
Uncertainty in Economic Evaluation: A Pragmatic Guide for Health Technology Assessment (HTA) Agencies in Resource-Constrained Settings
Abstract
Understanding the financial and health consequences if economic evaluation assumptions prove incorrect is essential for managing the risk associated with benefit package decisions, particularly in resource-constrained and overburdened healthcare systems. Yet these are also the settings t
Introduction of early health technology assessment for innovators, clinicians, and funders
Abstract
Health technology faces rising costs, system complexities, and gaps between development and coverage policies, limiting translation into practice. Traditional health technology assessment (HTA) evaluates technologies at late stages, providing little support if a technology fails to secur
Co-creating a process for integrating regulatory approval of late- stage clinical research into the Thailand’s Universal Benefit Package through Action Research
The research and development of new medicines is a lengthy and sequential process that spans more than a decade, culminating in regulatory approval based on evidence of quality, safety, and efficacy from clinical trial data. In Thailand, it takes nearly an additional decade for new medicines to be included in the Thailand National List of Essential
Can AI Really Help Us Prevent Diabetes and Hypertension in Thailand?
Non-communicable diseases (NCDs) are often called “silent killers”, but there is nothing silent about their impact. They remain one of the hardest public health battles to win. According to the World Health Organisation (WHO), they cause 43 million deaths worldwide and account for 75% of non-pandemi
From Potential to Practice: AI for Diabetes and Hypertension Prevention in Thailand
Background & RationaleNon-communicable diseases (NCDs) are the leading cause of death worldwide, responsible for 43 million deaths annually and accounting for 75% of all non-pandemic-related mortality globally [1]. Cardiovascular disease, diabetes, cancer, and chronic respiratory conditions drive this burden, yet most health systems remain orie
Combating a Global Public Health Threat: Antimicrobial Resistance – What are we doing?
Antimicrobial resistance (AMR) is one of the most pressing public health challenges worldwide. It occurs when antimicrobials—such as antibiotics, antifungals, antivirals, and antiparasitics—become ineffective against microorganisms like bacteria, fungi, viruses, and parasites. This resistance can le
Early Health Technology Assessment of Non-sputum-based Assays for Screening and Treatment Monitoring in a prospective cohort of pulmonary tuberculosis
Tuberculosis is caused by bacterium called Mycobacterium tuberculosis. It is a significant problem in Thailand as seen that in 2021 Thailand is in the World Health Organization’s list of 30 high-burden countries for tuberculosis. One of the problems about tuberculosis is inaccurate diagnosis due to insufficient sensitivity and specificity of prim
10 / Page